FDA Grants Priority Review for Levo Therapeutics’ New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
Read Levo Therapeutic, Inc.’s Full Article HERE. CHICAGO, IL, July 6, 2021 (Newswire.com) – Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for review and...
PWSA | USA and FPWR Share Community Update on FDA Patient Listening Session
On June 17, 2021, PWSA | USA and FPWR held a Patient Listening Session with the FDA to share our community’s experiences related to Prader-Willi syndrome (PWS). The purpose of this meeting was to promote dialogue between the FDA and members of the PWS patient community to ensure the FDA has a full understanding of...
Dr. Moris Angulo, MD Opens New Clinic in New York
We are pleased to announce that Dr. Moris Angulo M.D. has opened a new clinic, located in Bablyon, NY, and is accepting patients. Location: Center for Pediatric Specialty Care, 655 Deer Park Avenue, Babylon, NY 11702 To schedule an appointment, call 631-321-2100 ——————————————– Moris A. Angulo, M.D., was born in El Salvador, Central América and...
FPWR and PWSA|USA Request Regulatory Flexibility & Review of NDA for Intranasal Carbetocin
We request the flexibility afforded to other orphan indications when considering whether applications for treatments for PWS should be accepted for review. In a continuation of our joint advocacy efforts supporting the full review of potential drugs for PWS, FPWR and PWSA | USA have submitted a petition letter to the FDA requesting that they...